<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1018</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>8821654</PubmedId>
            <Abstract>Synthetic vaccines utilize specific antigenic epitopes in order to elicit a protective immune response. In this work we examined the immunogenicity of chimeric proteins expressing influenza epitopes and their ability, as single products or in various combinations, to protect mice from viral challenge. Oligonucleotides coding for three epitopes (HA91-108, NP55-69 and NP147-158) stimulating B cells, T helper cells and cytotoxic T lymphocytes (CTLs), respectively, were individually inserted into the flagellin gene of a Salmonella vaccine strain. Immunization of mice with the resultant hybrid flagella resulted in a specific humoral or cellular response. The protective efficacy of the chimeric flagella was evaluated by intranasal immunization of mice, without any adjuvant, and subsequent challenge with infectious virus. The construct containing the B-cell epitope by itself led to partial protection. However, the addition of the two T-cell epitopes augmented the protection in a significant manner. The protective immunity conferred by this combined vaccine, comprising the three epitopes, persisted for at least 7 months after the last boost, and was effective against several influenza A strains. Furthermore, this vaccine fully protected mice from a lethal challenge, and enhanced their recovery process. Our results indicate that stimulation of the different arms of the immune system is required for effective anti-influenza response, and demonstrate the applicability of such synthetic recombinant approach for preparing a broad spectrum influenza vaccine.</Abstract>
            <ArticleYear>1996</ArticleYear>
            <ArticlePages>85-92</ArticlePages>
            <ArticleTitle>Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Levi</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Arnon</LastName>
                    <ForeName>R</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.</Affiliations>
            <ArticleChemicalList>Influenza Vaccines;Vaccines, Synthetic</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; B-Lymphocytes(immunology; virology); Base Sequence; Cytotoxicity, Immunologic; Female; Influenza A virus(immunology); Influenza Vaccines(administration &amp; dosage; immunology); Lymphocyte Activation; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Orthomyxoviridae Infections(prevention &amp; control; virology); Species Specificity; T-Lymphocytes, Cytotoxic(immunology; virology); Vaccines, Synthetic(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>14</Volume>
                <Issue>1</Issue>
                <Title>Vaccine</Title>
                <Issn>0264-410X</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>NP 55-69</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RLIQNSLTIERMVLS</LinearSequence>
                        <StartingPosition>55</StartingPosition>
                        <EndingPosition>69</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P18072.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>444318</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 86</LocationOfData>
                <EpitopeId>54594</EpitopeId>
                <ReferenceStartingPosition>55</ReferenceStartingPosition>
                <ReferenceEndingPosition>69</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table I</LocationOfData>
                        <TCellId>14612</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RLIQNSLTIERMVLS</LinearSequence>
                                            <StartingPosition>55</StartingPosition>
                                            <EndingPosition>69</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P18072.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 55-69</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 innoculation with 10 micrograms peptide or 50 micrograms of peptide-carrier.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed at the base of the tail. Immunogen was either a  recombinant flagellin carrying the epitope (Fla-55), or the epitopic peptide.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 55-69</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RLIQNSLTIERMVLS</LinearSequence>
                                        <StartingPosition>55</StartingPosition>
                                        <EndingPosition>69</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P18072.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Proliferation in response to epitopic peptide is seen in lymphocytes of peptide and peptide-carrier immunized animals, although the response in the latter group is somewhat lower.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>14619</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>RLIQNSLTIERMVLS</LinearSequence>
                                            <StartingPosition>55</StartingPosition>
                                            <EndingPosition>69</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P18072.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 55-69</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>3 innoculations 3 wk apart with 25 micrograms of peptide-carrier.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen was a recombinant flagellin carrying the epitope (Fla-55) alone or in combination with 2 other epitope-carrier constructs.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Viral titers following sublethal intranasal challenge with the source species 1 week after the final immunization are not reduced in comparison to those of carrier immunized animals. By contrast, in combination with flagellins carrying another epitope (NP147, CTL epitope) or 2 other epitopes (NP147 and HA91, B cell epitope), it effectively reduces the viral load in lungs after challenge. If the challenge is performed one month after the final immunization, the triple combination is the only effective vaccine. This is also the most effective vaccine for inducing long term (7 month) protection to challenge in terms of viral load. After lethal dose challenge 1 or 7 months after the final immunization, survival rate and recovery from infection is enhanced in triple combination vaccinated animals.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA 91-108</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SKAFSNCYPYDVPDYASL</LinearSequence>
                        <StartingPosition>91</StartingPosition>
                        <EndingPosition>108</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q8V285</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>444318</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 86</LocationOfData>
                <EpitopeId>58783</EpitopeId>
                <ReferenceStartingPosition>91</ReferenceStartingPosition>
                <ReferenceEndingPosition>108</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>14639</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SKAFSNCYPYDVPDYASL</LinearSequence>
                                            <StartingPosition>91</StartingPosition>
                                            <EndingPosition>108</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q8V285</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA 91-108</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>3 innoculations 3 wk apart with 25 micrograms of recombinant proteins.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with  peptide-carrier construct (Fla-91)  or a  mixture of 2 (Fla-91 + Fla147) or 3 (Fla-55+Fla-147+Fla-91) constructs.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>559</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The challenge was performed with different strains to asses cross-protective immunity. Viral titers following sublethal challenge with A/Aichi (H3N2), A/England (H3N2) or A/Japanese (H2N2) 1 month after the final immunization with the epitope-carrier construct are similar to those of control immunized mice. If coadministered with a CTL epitope (NP147) construct or in a  triple combination of epitopes (NP55, NP147 and HA91) on flagellin carriers, virus loads are significantly reduced.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus (A/Texas/1/77(H3N2))</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>14638</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SKAFSNCYPYDVPDYASL</LinearSequence>
                                            <StartingPosition>91</StartingPosition>
                                            <EndingPosition>108</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q8V285</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA 91-108</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>3 innoculations 3 wk apart with 25 micrograms of recombinant proteins.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed with  peptide-carrier construct (Fla-91) or a  mixture of 3 (Fla-55+Fla-147+Fla-91) constructs.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>559</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Viral titers following sublethal challenge with A/Texas/77 1week after final immunization are not reduced in comparison to those of carrier immunized animals. By contrast, in combination with flagellins carrying another 2 T cell epitopes (NP147 and NP55), it effectively reduces the viral load in lungs after challenge. If challenge is performed one month after the final immunization, the triple combination is the only effective vaccine. This is also the most effective vaccine for inducing long term (7 month) protection to challenge in terms of viral load. After lethal dose challenge 1 or 7 months after the final immunization, survival rate and recovery from infection is enhanced in triple combination vaccinated animals.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus (A/Texas/1/77(H3N2))</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table I</LocationOfData>
                        <TCellId>14633</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SKAFSNCYPYDVPDYASL</LinearSequence>
                                            <StartingPosition>91</StartingPosition>
                                            <EndingPosition>108</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q8V285</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA 91-108</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 innoculation with 10 micrograms peptide or 50 micrograms of peptide-carrier.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed at the base of the tail. Immunogen was either a  recombinant flagellin carrying the epitope (Fla-91), or the epitopic peptide.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 91-108</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SKAFSNCYPYDVPDYASL</LinearSequence>
                                        <StartingPosition>91</StartingPosition>
                                        <EndingPosition>108</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q8V285</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Proliferation in response to epitopic peptide is not seen in lymphocytes of peptide and peptide-carrier immunized animals, which was expected because this a previously known B cell epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP 147-158</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TYQRTRALVRTG</LinearSequence>
                        <StartingPosition>147</StartingPosition>
                        <EndingPosition>158</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P18072.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>444318</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 86</LocationOfData>
                <EpitopeId>67437</EpitopeId>
                <ReferenceStartingPosition>147</ReferenceStartingPosition>
                <ReferenceEndingPosition>158</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure I</LocationOfData>
                        <TCellId>15627</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYQRTRALVRTG</LinearSequence>
                                            <StartingPosition>147</StartingPosition>
                                            <EndingPosition>158</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P18072.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 147-158</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>3 innoculations 3 wk apart with 25 micrograms of peptide-carrier.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunogen was a recombinant flagellin carrying the epitope (Fla-147) alone or in combination with 2 other epitope-carrier constructs.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Virus titers following sublethal intranasal challenge with source species 1week afterthe final immunization are not reduced in comparison to those of carrier immunized animals. By contrast, in combination with flagellins carrying another epitope (NP55, Th epitope) or two other epitopes (NP55 and HA91, B cell epitope), it effectively reduces the viral load in lungs after challenge. If challenge is performed one month after the final immunization, the triple combination is the only effective vaccine. This is also the most effective vaccine for inducing long term (7 month) protection to challenge in terms of viral load. After lethal dose challenge 1 or 7 months after the final immunization, survival rate and recovery from infection is enhanced in triple combination vaccinated animals.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table I</LocationOfData>
                        <TCellId>15626</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TYQRTRALVRTG</LinearSequence>
                                            <StartingPosition>147</StartingPosition>
                                            <EndingPosition>158</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P18072.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>444318</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>NP 147-158</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P06177.2</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>596</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 innoculation with 10 micrograms peptide or 50 micrograms of peptide-carrier.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Immunization was performed at the base of the tail. Immunogen was either a  recombinant flagellin carrying the epitope (Fla-147), or the epitopic peptide.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>170</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP 147-158</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TYQRTRALVRTG</LinearSequence>
                                        <StartingPosition>147</StartingPosition>
                                        <EndingPosition>158</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P18072.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>444318</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Proliferation in response to epitopic peptide is seen in lymphocytes of peptide and peptide-carrier immunized animals, although the response in the latter group is somewhat lower.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

